OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging
Bishwas Chamling, Michael Bietenbeck, Dennis Korthals, et al.
Clinical Research in Cardiology (2022) Vol. 112, Iss. 3, pp. 353-362
Open Access | Times Cited: 22
Bishwas Chamling, Michael Bietenbeck, Dennis Korthals, et al.
Clinical Research in Cardiology (2022) Vol. 112, Iss. 3, pp. 353-362
Open Access | Times Cited: 22
Showing 22 citing articles:
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid
Pablo García‐Pavía, Fabian aus dem Siepen, Erwan Donal, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 3, pp. 239-250
Closed Access | Times Cited: 142
Pablo García‐Pavía, Fabian aus dem Siepen, Erwan Donal, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 3, pp. 239-250
Closed Access | Times Cited: 142
Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine
Esther Gonzalez-Lopez, Mathew S. Maurer, Pablo García‐Pavía
European Heart Journal (2025)
Open Access | Times Cited: 3
Esther Gonzalez-Lopez, Mathew S. Maurer, Pablo García‐Pavía
European Heart Journal (2025)
Open Access | Times Cited: 3
Myocardial Late Gadolinium Enhancement (LGE) in Cardiac Magnetic Resonance Imaging (CMR)—An Important Risk Marker for Cardiac Disease
Claudia Meier, Michel Eisenblätter, Stephan Gielen
Journal of Cardiovascular Development and Disease (2024) Vol. 11, Iss. 2, pp. 40-40
Open Access | Times Cited: 12
Claudia Meier, Michel Eisenblätter, Stephan Gielen
Journal of Cardiovascular Development and Disease (2024) Vol. 11, Iss. 2, pp. 40-40
Open Access | Times Cited: 12
Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment
Svenja Ney, Roman Johannes Gertz, Lenhard Pennig, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 1, pp. 284-284
Open Access | Times Cited: 7
Svenja Ney, Roman Johannes Gertz, Lenhard Pennig, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 1, pp. 284-284
Open Access | Times Cited: 7
Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment
Julia Vogel, Alexander Carpinteiro, Peter Luedike, et al.
Current Heart Failure Reports (2024) Vol. 21, Iss. 4, pp. 305-321
Open Access | Times Cited: 7
Julia Vogel, Alexander Carpinteiro, Peter Luedike, et al.
Current Heart Failure Reports (2024) Vol. 21, Iss. 4, pp. 305-321
Open Access | Times Cited: 7
Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy
Stephan Dobner, Benedikt Bernhard, Lorenz Ninck, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 5, pp. 2759-2768
Open Access | Times Cited: 6
Stephan Dobner, Benedikt Bernhard, Lorenz Ninck, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 5, pp. 2759-2768
Open Access | Times Cited: 6
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis
Jie Wang, Hongyu Chen, Zihuan Tang, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102172-102172
Open Access | Times Cited: 11
Jie Wang, Hongyu Chen, Zihuan Tang, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102172-102172
Open Access | Times Cited: 11
Myocardial T1 Mapping, Left Ventricular Parameters, and Cardiac Biomarkers in Wild-Type Transthyretin Amyloid Cardiomyopathy Before and After Tafamidis Treatment
Yuki Ikegami, Toshiro Kitagawa, Yoshiharu Sada, et al.
Circulation Reports (2025) Vol. 7, Iss. 3, pp. 198-206
Open Access
Yuki Ikegami, Toshiro Kitagawa, Yoshiharu Sada, et al.
Circulation Reports (2025) Vol. 7, Iss. 3, pp. 198-206
Open Access
Diagnostic value of bone scintigraphy versus CMR in cardiac amyloidosis
J Obergassel, Michael Bietenbeck, Nuriye Akyol, et al.
Journal of Cardiovascular Magnetic Resonance (2025), pp. 101859-101859
Open Access
J Obergassel, Michael Bietenbeck, Nuriye Akyol, et al.
Journal of Cardiovascular Magnetic Resonance (2025), pp. 101859-101859
Open Access
Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study
Cheng‐Hsuan Tsai, Chi‐Chao Chao, Sung‐Tsang Hsieh, et al.
Orphanet Journal of Rare Diseases (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 9
Cheng‐Hsuan Tsai, Chi‐Chao Chao, Sung‐Tsang Hsieh, et al.
Orphanet Journal of Rare Diseases (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 9
Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study
Richard J. Nies, Svenja Ney, Ingrid Kindermann, et al.
ESC Heart Failure (2024)
Open Access | Times Cited: 2
Richard J. Nies, Svenja Ney, Ingrid Kindermann, et al.
ESC Heart Failure (2024)
Open Access | Times Cited: 2
Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval
Fabian aus dem Siepen, C. Meißner, Eva Hofmann, et al.
Amyloid (2024) Vol. 31, Iss. 3, pp. 226-231
Closed Access | Times Cited: 2
Fabian aus dem Siepen, C. Meißner, Eva Hofmann, et al.
Amyloid (2024) Vol. 31, Iss. 3, pp. 226-231
Closed Access | Times Cited: 2
Cardiac MRI T1 and T2 Mapping as a Quantitative Imaging Biomarker in Transthyretin Amyloid Cardiomyopathy
Shinpei Yamaguchi, Seitaro Oda, Masafumi Kidoh, et al.
Academic Radiology (2023) Vol. 31, Iss. 2, pp. 514-522
Closed Access | Times Cited: 4
Shinpei Yamaguchi, Seitaro Oda, Masafumi Kidoh, et al.
Academic Radiology (2023) Vol. 31, Iss. 2, pp. 514-522
Closed Access | Times Cited: 4
Impact of Tafamidis on Delaying Clinical, Functional, and Structural Cardiac Changes in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy
Giuseppe Palmiero, Emanuele Monda, Federica Verrillo, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 13, pp. 3730-3730
Open Access | Times Cited: 1
Giuseppe Palmiero, Emanuele Monda, Federica Verrillo, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 13, pp. 3730-3730
Open Access | Times Cited: 1
Monitoring the Efficacy of Tafamidis in ATTR Cardiac Amyloidosis by MRI-ECV: A Systematic Review and Meta-Analysis
Shingo Kato, Mai Azuma, Nobuyuki Horita, et al.
Tomography (2024) Vol. 10, Iss. 8, pp. 1303-1311
Open Access | Times Cited: 1
Shingo Kato, Mai Azuma, Nobuyuki Horita, et al.
Tomography (2024) Vol. 10, Iss. 8, pp. 1303-1311
Open Access | Times Cited: 1
Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy
Ting‐Wei Kao, Yi-Hsin Hung, An‐Li Yu, et al.
JACC Advances (2024) Vol. 4, Iss. 2, pp. 101511-101511
Open Access | Times Cited: 1
Ting‐Wei Kao, Yi-Hsin Hung, An‐Li Yu, et al.
JACC Advances (2024) Vol. 4, Iss. 2, pp. 101511-101511
Open Access | Times Cited: 1
Tafamidis for cardiac transthyretin amyloidosis: application in a real-world setting in Germany
Caroline Morbach, Aikaterini Papagianni, Sandra Ihne, et al.
Clinical Research in Cardiology (2023) Vol. 113, Iss. 5, pp. 653-655
Open Access | Times Cited: 3
Caroline Morbach, Aikaterini Papagianni, Sandra Ihne, et al.
Clinical Research in Cardiology (2023) Vol. 113, Iss. 5, pp. 653-655
Open Access | Times Cited: 3
Multi-parametric non-contrast cardiac magnetic resonance for the differentiation between cardiac amyloidosis and hypertrophic cardiomyopathy
Henning Steen, Moritz Montenbruck, Alexandros Kallifatidis, et al.
Clinical Research in Cardiology (2023) Vol. 113, Iss. 3, pp. 469-480
Closed Access | Times Cited: 1
Henning Steen, Moritz Montenbruck, Alexandros Kallifatidis, et al.
Clinical Research in Cardiology (2023) Vol. 113, Iss. 3, pp. 469-480
Closed Access | Times Cited: 1
Inverse correlation between age of onset and myocardial amyloid deposition quantified by 99mTc-PYP scintigraphy in patients with wild-type transthyretin amyloid cardiomyopathy
Hiroshi Kanaya, Shinya Shiraishi, Kouji Ogasawara, et al.
Annals of Nuclear Medicine (2024) Vol. 38, Iss. 9, pp. 744-753
Open Access
Hiroshi Kanaya, Shinya Shiraishi, Kouji Ogasawara, et al.
Annals of Nuclear Medicine (2024) Vol. 38, Iss. 9, pp. 744-753
Open Access
Transthyretin Stabilizer Therapy in Patients With Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis
Hilária Saugo Faria, BRUNA POZZEBON PEIXOTO, Milene Vitória Sampaio Sobral, et al.
American Journal of Therapeutics (2024) Vol. 32, Iss. 1, pp. e84-e88
Closed Access
Hilária Saugo Faria, BRUNA POZZEBON PEIXOTO, Milene Vitória Sampaio Sobral, et al.
American Journal of Therapeutics (2024) Vol. 32, Iss. 1, pp. e84-e88
Closed Access
Effect of Diflunisal in Patients with Transthyretin Cardiomyopathy: A Pilot Study
Andrea Camblor Blasco, Ana Devesa, Luis Nieto Roca, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 17, pp. 5032-5032
Open Access
Andrea Camblor Blasco, Ana Devesa, Luis Nieto Roca, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 17, pp. 5032-5032
Open Access
Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy
Stephan Dobner, Benedikt Bernhard, Monika Wieser, et al.
Amyloid (2023) Vol. 31, Iss. 2, pp. 145-147
Closed Access
Stephan Dobner, Benedikt Bernhard, Monika Wieser, et al.
Amyloid (2023) Vol. 31, Iss. 2, pp. 145-147
Closed Access
